Individually rare, collectively common – how do we transform the lives of people with rare diseases?
Clear national policy, collaboration with patients, and reviewing progress are key to tackling diagnosis, treatment and care challenges.
Clear national policy, collaboration with patients, and reviewing progress are key to tackling diagnosis, treatment and care challenges.
Partnership between the NHS, industry and research institutes is crucial to enable the UK to reach its clinical research potential.
ByBritain has a strong background in pharmaceuticals and clinical trials but is struggling to achieve its full potential.
Why pharmaceutical companies play a role in driving progress.
ByThe answer is yes, but the window of opportunity is closing.
ByThe chief executive of the Association of the British Pharmaceutical Industry on joining Horizon, R&D policy, and his morning run.
ByThe rapid advancement of technology must be used to fight disease.
By